App-Quantinova.ai

Circulating tumor cells (CTCs) as a predictor of metastatic disease in patients with biochemical recurrence (BR) of prostate cancer with equivocal scan results.

Jeanny B. Aragon-Ching - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).

Dea Nagy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.

Dana E. Rathkopf - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

ARN-509

Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.

Sylvestre Le Moulec - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Is docetaxel-prednisone (DP) feasible in frail elderly (age 75 or older) patients with castration-resistant metastatic prostate cancer (CRMPC)- GERICO10-GETUG P03 trial: A trial from elderly and genitourinary oncology UNICANCER groups.

Loic Mourey - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Prednisone

Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy.

Michael Rink - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

Paoletti C - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Protein-bound paclitaxel

Correlation between blood markers of hemostasis and circulating tumor cells (CTCs) in early breast cancer patients

Mego M - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Genome-wide analysis of copy number variations and mutation profiles of single circulating tumour cells using massively parallel paired-end sequencing

Peeters DJE - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Isolation and expression profiling of EpCAM-negative circulating tumor cells in human and xenograft models of breast cancer

Lang JE - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

ST-1

Assessment of circulating tumor cells (CTC) by RT/PCR as a surrogate marker for PFS in metastatic breast cancer (MBC)

Saber MM - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Human chorionic gonadotropin

Prognostic value of CTC detection by RT-PCR and the CellSearch system before first-line chemotherapy in metastatic breast cancer

Agelaki S - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer

Kasimir-Bauer S - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Role of miR-186 in circulating tumor cells (CTCs)-mediated metastasis in breast cancer

Tucker S - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Breast cancer brain metastasis: Interrogating mechanisms of brain colonization by DEPArray-selected CTC subsets and biomarker discovery

Marchetti D - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

Detection and monitoring of circulating endothelial cells, circulating tumor cells and disseminated tumor cells during neoadjuvant breast cancer treatment including bevacizumab

Mathiesen RR - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Bevacizumab

Prospective comparison of prognostic factors in patients starting a third line of chemotherapy for metastatic breast cancer: An ancillary study to the CirCe01 trial

Helissey C - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study

Viens P - San Antonio Breast Cancer Symposium (SABCS) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Bevacizumab

Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in 497 First-Line Metastatic Breast Cancer Patients

Giordano A - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Circulating Tumor Cells (CTC) May Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer Results of the German SUCCESS C Trial

Jaeger BAS - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fluorescein sodium

Filters

1671 Abstracts